Japanese pharmaceutical technology company developing LAVURCHIN (SQAP), an anticancer radiosensitizer intended to improve cancer treatment efficacy
Japanese pharmaceutical technology company developing LAVURCHIN (SQAP), an anticancer radiosensitizer intended to improve cancer treatment efficacy. Research includes radiation therapy and chemotherapy applications across human cancers and canine tumors.